Viatris’ Insulin Aspart Endorsed By EMA
Kixelle Biosimilar Rival To NovoRapid Receives CHMP Positive Opinion
Viatris has received a positive opinion from the EMA’s CHMP recommending granting a pan-European marketing authorization for the firm’s insulin aspart biosimilar rival to NovoRapid.
